Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.67 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.67 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353050 | 0.91 | MAPT (0.57) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL13552273 | 0.90 | MAPT (0.56) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL4217444 | 0.85 | MAPT (0.53) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL1675546 | 0.83 | MAPT (0.51) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL4217442 | 0.83 | MAPT (0.51) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL4217436 | 0.83 | MAPT (0.51) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL3519645 | 0.82 | KDM4E (0.62) | MAPTHPGD | |
| SCHEMBL8138421 | 0.82 | MAPT (0.50) | MAPTMEN1KMT2ALMNANPSR1 | |
| SCHEMBL77732 | 0.82 | MEN1 (0.63) | MAPTMEN1KMT2ANPSR1HPGD | |
| SCHEMBL9254147 | 0.82 | MAPT (0.55) | MAPTMEN1KMT2ALMNANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | APODACA RICHARD (US) | 2012-12-20 | — | — | US | disclosed |
| US-8273762-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2012-09-25 | — | — | US | disclosed |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-23 | — | — | US | disclosed |
| US-7754882-B2 | Hexahydro-pyrrolo-isoquinoline compounds | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-13 | — | — | US | disclosed |
| EP-1893613-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006138604-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS FOR THE TREATMENT OF CNS DISORDERS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | WO | disclosed |
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293316-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | MAPT 708/4885MEN1 3014/4885KMT2A 1059/4885 |
| US-20100240648-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | MAPT 708/4885MEN1 3014/4885KMT2A 1059/4885 |
| US-20120321559-A1 | HEXAHYDRO-PYRROLO-ISOQUINOLINE COMPOUNDS | HRH3, HRH1, HRH4 | MAPT 708/4885MEN1 3014/4885KMT2A 1059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.